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Previous genetic association studies have failed to identify loci robustly associated with 
sepsis, and there have been no published genetic association studies or polygenic risk score 
analyses of patients with septic shock, despite evidence suggesting genetic factors may be 
involved. We systematically collected genotype and clinical outcome data in the context of a 
randomized controlled trial from patients with septic shock to enrich the presence of disease 
associated genetic variants. We performed genome-wide association studies of susceptibility 
and mortality in septic shock using 493 patients with septic shock and 2442 population 
controls, and polygenic risk score analysis to assess genetic overlap between septic shock 
risk/mortality with clinically relevant traits. One variant, rs9489328, located in AL589740.1 
non-coding RNA, was significantly associated with septic shock (p = 1.05 x 10-10), however is 
likely a false- positive. We were unable to replicate variants previously reported to be 
associated (p < 1.00 x 10-6 in previous scans) with susceptibility to, and mortality from sepsis. 
Polygenic risk scores for hematocrit and granulocyte count were negatively associated with 
28-day mortality (p = 3.04 x 10-3; p = 2.29 x 10-3), and scores for C-reactive protein levels 
were positively associated with susceptibility to septic shock respectively (p = 1.44 x 10-3). 
Results suggest common variants of large effect do not influence septic shock susceptibility, 
mortality, and resolution, however genetic predispositions to clinically relevant traits are 






Sepsis is an abnormal host response to infection, resulting in organ and tissue damage (Singer 
et al., 2016). Septic shock is the most severe form of sepsis, with a significantly higher 
mortality rate due to profound circulatory and metabolic abnormalities (Singer et al., 2016). 
The annual worldwide incidence of sepsis in adults has been estimated at 31.5 million cases 
per year, of which 5.3 million instances are fatal (Fleischmann et al., 2016). Sepsis poses a 
high financial burden on the economy, with United States in-hospital costs for each episode 
averaging US$22,100 (Angus et al., 2001). 
Individuals vary widely in terms of their susceptibility to sepsis and their prognosis, and this 
heterogeneity is thought to be in part due to host genetic factors (Sørensen et al., 1988). A 
genetic basis for susceptibility to sepsis has long been suspected since epidemiological studies 
found that adopted individuals had markedly increased risk of mortality from infection when 
a biological parent had died prematurely from infection, but no corresponding increase risk in 
mortality when an adoptive parent had died from infection (Sørensen et al., 1988). However, 
previous candidate gene and genome-wide association studies (GWAS) of sepsis have had 
limited success in identifying genetic loci robustly associated with the disease and outcomes 
(Rautanen et al., 2015; Scherag et al., 2016; Srinivasan et al., 2017). This is possibly due to 
lack of statistical power caused by a combination of small sample sizes and heterogeneity of 
both the patient population and of the phenotype (Rautanen et al., 2015; Scherag et al., 2016; 
Srinivasan et al., 2017). 
We designed the ADRENAL Genome-Wide Association Study (ADRENAL-GWAS) to 
investigate the genetic influences on susceptibility to, resolution of, and mortality from septic 
shock. We performed GWAS on a cohort of critically ill patients who were enrolled into a 




(ADRENAL) (Venkatesh et al., 2018). We sampled individuals suffering from septic shock, 
as opposed to sepsis, on the rationale that focusing on extreme cases will increase statistical 
power to detect genetic associations as has been done successfully in the case of many other 
diseases and complex traits (Barnett et al., 2013). 
To improve our understanding of genetic basis of sepsis, we performed additional analyses 
with increased power to complement the knowledge gained from GWAS. These include gene 
and pathway based analysis and evaluation of polygenic risk scores. To our knowledge these 
approaches have not been used in the evaluation of sepsis or septic shock.   
Methods 
Study Participants 
The ADRENAL Genome-Wide Association Study (ADRENAL-GWAS) is a sub-study 
within the main ADRENAL trial (ClinicalTrials.gov number, NCT01448109) designed to 
investigate the genetics and genomics of septic shock. All ADRENAL participants who were 
admitted to 27 participating hospital sites in three countries (Australia, New Zealand, and the 
United Kingdom) were eligible for the ADRENAL-GWAS substudy. The inclusion/exclusion 
criteria were similar to the original ADRENAL study and summarised in Supplementary 
Methods S1 (Venkatesh et al., 2018). Blood samples from ADRENAL-GWAS participants (n 
= 578) were collected at the time of randomisation, prior to administration of 
corticosteroids/placebo. Blood was collected into 2 x 2.5 mL EDTA, 2 x 2.5 mL serum blood 
collection vacuettes (Interpath; Cat. No. 455071), and 1 x 2.5 mL PAXgene RNA Vacutainer 
(Becton Dickinson; Cat. No. 762165). 
An unpublished genotyped cohort consisting of 3624 individuals collected at the QIMR 
Berghofer Medical Research Institute (QIMRB) was used as a control group in the case- 




‘healthy’ individuals) used in studies of reproductive health or melanoma risk factors. DNA 
was extracted from either blood or saliva samples. Notably, the controls, while drawn from an 
unselected cohort, were deliberately chosen as they were genotyped using the same array, and 
had similar underlying ancestries to the ADRENAL participants.  
Genotyping and Quality Control 
ADRENAL-GWAS genomic DNA extractions were performed on 200 μl of whole blood 
using the QIAsymphony SP instrument according to the manufacturer’s protocol 
(QIAsymphony DSP DNA Mini Kit, Cat. No. 937236). Genomic DNA was eluted in 100 μl 
of Buffer ATE and quantified using the Trinean Dropsense 96. Samples were genotyped on 
the Illumina Infinium Global Screening Array-24+ v1.0 (20005136). The arrays were scanned 
on an Illumina iScan system and the raw fluorescence intensity data was normalized and 
clustered for each sample using Illumina Genome Studio (v 2.0.3). Genotypes were called 
using the standard Illumina GSA-24v1-0_A6 Cluster File. 
In the QIMRB cohort, DNA was extracted from either blood or saliva samples, and genotyped 
using the Illumina Infinium Global Screening Array-24+ v1.0. Genotype data were screened 
for genotyping quality (GenCall < 0.7), single nucleotide polymorphism (SNP) and individual 
call rates (< 0.95), Hardy Weinberg Equilibrium (HWE) failure (P < 10-6), and minor allele 
frequency (MAF < 0.01). As these samples were genotyped in the context of a larger project, 
the data were integrated with the larger QIMRB genotype project and the data were checked 
for pedigree, sex and Mendelian errors, and for non-European ancestry. 
The PLINK v1.90b3.31 software package was used to carry out a number of standard quality 
control (QC) procedures (Chang et al., 2015). A detailed breakdown of QC procedures can be 






The primary outcome was death from any cause at 90 days, and the secondary outcomes were 
death at 28 days, shock resolution, and susceptibility to septic shock. For diagnostic criteria 
and definitions of these outcomes see Supplementary Methods S1 and Supplementary 
Methods S2.  
Statistical Power Analyses 
We investigated power to detect variants at genome-wide levels of significance (α = 5 x 10-8) 
and also power to replicate variants reported in previous genome-wide association studies of 
susceptibility to sepsis and 28-day mortality (α = 0.05) using the Genetic Association Study 
Power Calculator (Johnson & Abecasis, 2017). The relationship between heterozygous 
relative risk (RR; a measure of genetic effect size) and statistical power is presented in the 
Supplementary Methods S4. We assumed a lifetime risk of septic shock of 1%, a 
multiplicative model of disease risk (on the odds scale), that the risk locus had been 
genotyped (r2 = 1), and we matched the GWAS sample sizes (see Supplementary Methods 
S4). 
The susceptibility to septic shock GWAS had the most statistical power of all the GWAS, 
where for genome-wide association analyses (α = 5 x 10-8), we expect 80% power to detect 
variants with a heterozygous RR of 1.55 and 2.52 for a risk allele frequency of 0.50 and 0.05 
respectively. For replication of previous findings (α = 0.05), there is 80% power to detect 
variants with a heterozygous RR of 1.22 and 1254 for a risk allele frequency of 0.50 and 0.05 






Genome-Wide Association Analyses 
We performed logistic regression analysis assuming an underlying additive genetic model (on 
the log scale) as implemented in PLINK across the genome on septic shock patients 
(ADRENAL-GWAS) and healthy controls (QIMRB). The first five principal components 
(PCs) from a PC analysis of the cleaned merged GWAS dataset were used as covariates. 
Further, we performed logistic regression analysis, on ADRENAL-GWAS participants only 
(no controls), assuming an underlying additive genetic model using PLINK for 28-day 
mortality, 90-day mortality, and shock resolution. Covariates included sex and the first five 
PCs.  
Look Up of Previously Reported Variants  
Suggestive associations (p ≤ 1 x 10-5) reported in analyses of 28-day survival/mortality in 
sepsis (Rautanen et al. survivors = 1194, non-survivors = 359; Scherag et al. survivors = 
2803, non-survivors = 667) were queried in our 28-day mortality GWAS summary statistics 
(Rautanen et al., 2015; Scherag et al., 2016). Likewise, SNPs that reached suggestive 
significance in a susceptibility GWAS of premature infants (Srinivasan et al. cases = 351, 
controls = 406) and two GWAS from the UK Biobank (UKBB) were also queried in our 
susceptibility to septic shock GWAS summary statistics (Sudlow et al., 2015; Srinivasan et 
al., 2017; Neale, 2018). The UKBB analyses were originally performed on cohorts defined as 
having 'other septicaemia’ (Phecode_A41, cases = 1096, controls = 360,098) and 







Gene- and Pathway-Based Analyses 
A number of gene-/pathway-based analyses were performed on the GWAS data for each 
outcome to identify genes or pathways which were enriched through combining statistical 
information across many markers within a gene, or within multiple genes in a pathway, and 
testing for association with the outcome. The Complex-Traits Genetics Virtual Lab (CTG-
VL) implemented version of FastBAT was used to perform gene-based association analyses 
on the summary level results (Bakshi et al., 2016; Cuéllar-Partida et al., 2019). Data-Driven 
Expression-Prioritized Integration for Complex Traits (DEPICT v.1 beta) was used to identify 
enriched genes, gene-sets/pathways, and cell/tissue types from independent lead variants (r2 = 
0.2, MAF > 0.05, clump-kb 1000), which reached suggestive significance (p ≤ 1 x 10-5) (Pers 
et al., 2015). 
Polygenic Risk Score Analyses 
We downloaded GWAS summary-statistics for phenotypes with suspected shared genetic 
aetiology with sepsis, or requested the data from the authors (Sudlow et al., 2015; Zheng et 
al., 2017; Neale, 2019). These included large-scale GWAS meta-analyses for hematocrit, 
diastolic blood pressure (DBP), granulocyte count, white blood cell count (WBC), coronary 
artery disease, type-2 diabetes (T2D), C-reactive protein levels (CRP), ‘septicaemia/sepsis’ 
(Phecode_20002_1657), and ‘other septicaemia’ (Phecode_A41) (International Consortium 
for Blood Pressure Genome-Wide Association Studies et al., 2011; Sudlow et al., 2015; Astle 
et al., 2016; Scott et al., 2017; Ligthart et al., 2018). Polygenic risk scores (PRS) for height 
were also constructed as a negative control (Yengo et al., 2018). Independent SNP signals 
from each set of summary statistics were identified using PLINK (r2 = 0.1, clump-kb = 1000). 
Genome-wide PRS for each of the above diseases/traits were generated for the 493 septic 




scored on the number of risk alleles they carried for each variant (at the thresholds p < 5 x 10-
8, 5 x 10-6, 0.01, 0.5, 1), weighted by regression coefficients from the respective GWAS 
(Evans et al., 2013). To investigate relationships between septic shock and the various traits, 
28-day mortality was regressed on the PRS generated for each septic shock individual using 
logistic regression, with age, sex, and the first five PCs from the GWAS as covariates. 
Disease status (logistic regression) was regressed against the scores generated for the 
case/control cohort, with the first five PCs used as covariates.  
Results 
From May 2014 through April 2017, 578 patients were enrolled into the GWAS sub-study at 
27 hospital sites. The Intensive care units were in Australia (18 sites), New Zealand (4), and 
the United Kingdom (5). Of the 578 patients enrolled, 300 were assigned to receive 
hydrocortisone and 278 to receive placebo. A total of 493 septic shock cases passed QC, and 
of the 3624 QIMRB controls, 2442 individuals passed (Supplementary Methods S3). All 
individuals passing QC were of European descent (Supplementary Figure S1). A breakdown 
of the outcomes, sample sizes, and characteristics in ADRENAL-GWAS cases and QIMRB 
controls can be found in Error! Reference source not found.. Treatment had no significant 
effect on 90-day mortality, 28-day mortality or shock resolution (p = 0.35, 0.62, 0.09) and 
therefore had no confounding effect on the GWAS. GWAS were performed for all outcomes, 
however we focussed the latter analyses on 28-day mortality and susceptibility to septic shock 
to replicate past GWAS of sepsis, to be consistent, and reduce the burden of multiple testing 
correction. 
 






Genome-Wide Association Studies 
GWAS were performed for susceptibility to shock (493 cases, 2442 controls), 28-day 
mortality (90 non-survivors, 403 survivors), 90-day mortality (112 non-survivors, 381 
survivors) and shock resolution (34 unresolved, 459 resolved). The Manhattan plots for each 
GWAS are presented in Figure 1. The T allele of the genotyped SNP rs9489328, was the only 
genetic variant to be significantly associated with any of the outcomes. This SNP sits within a 
non-coding RNA gene AL589740.1 (Supplementary Figure S4), and was associated with 
decreased risk of septic shock (p = 1.05 x 10-10) (Table 2). Three genetic variants, 
rs11167801, rs7698838, and rs17128291, were associated with shock resolution at suggestive 
levels of significance (p < 1 x 10-6). Quantile-Quantile plots (Supplementary Figure S5) and 
genomic inflation factors (Supplementary Table S2) suggest that the GWAS results were not 
systematically inflated. 
{TABLE 2 ABOUT HERE} 
[INSERT FIG 1 HERE] 
Figure 1. Manhattan plots for (A) Susceptibility to Septic Shock, (B) 28-Day Mortality, (C) 
90-Day Mortality, and (D) Resolution of Shock Genome-Wide Association Studies. Plots 
were generated using the Complex-Traits Genetics Virtual Lab (Cuéllar-Partida et al., 2019). 
The blue dotted line denotes the ‘suggestive significance’ threshold of p < 1 x 10-6, and the 
red line denotes the ‘genome-wide significance’ threshold of p < 5 x 10-8, and the lead single 
nucleotide polymorphisms surpassing these thresholds are annotated. Only genetic variants 







This study failed to replicate (p < 0.05) any SNPs previously associated (p ≤ 1 x 10-5) with 
28-day sepsis mortality/survival and susceptibility to sepsis (Supplementary Table S3 and 
Supplementary Table S4). SNPs that reached suggestive significance (p ≤ 1 x 10-5) from the 
UKBB sepsis related phenotypes also failed to replicate in the present septic shock GWAS 
(Supplementary Table S4) (Rautanen et al., 2015;  Scherag et al., 2016; Srinivasan et al., 
2017; Neale, 2018). 
Gene- and Pathway-Based Analyses 
The top five gene associations from FastBAT analyses for each outcome are summarised in 
Table 3. No genes reached the significance threshold (p ≤ 2.5 x 10-6). DEPICT did not identify 
any genes, pathways, cells or tissue types to be significantly enriched across all the GWAS at 
false discovery rate < 5%, however the top five genes, pathways, and tissues can be found in 
Supplementary Table S5, Supplementary Table S6 and Supplementary Table S7. 
{TABLE 3 ABOUT HERE} 
Polygenic Risk Score Analysis 
PRS derived from GWAS summary statistics for ten different traits were calculated in the 
septic shock 28 day survivors and non-survivors, as well as in all septic shock patients and 
controls (Table ). The p-value threshold for statistical significance after Bonferroni correction 
for multiple testing is 5.0 x 10-3 (ten phenotypes). There were three significantly associated 
PRS in the expected direction. PRS for higher hematocrit and granulocyte count were 
negatively associated with 28-day mortality (p = 3.04 x 10-3 and 2.29 x 10-3). PRS for higher 




all significant phenotypes, PRS constructed using SNPs that reached the less conservative p-
value thresholds were more predictive than PRS constructed using only SNPs that met more 
conservative thresholds. There were no significant associations with the negative control 
height. 
{TABLE 4 ABOUT HERE} 
Discussion 
The current study presents, to our knowledge, the first report of genetic association analyses 
and the use of a polygenic risk score analytical approach in an exclusive cohort of patients 
with septic shock. The robust clinical outcome data was collected systematically in the 
context of a randomized controlled trial, and the analyses focused on patient centered 
outcomes. Comparable genetic studies consist only of small cohorts of patients with sepsis 
(Rautanen et al., 2015; Scherag et al., 2016; Srinivasan et al., 2017). We attempted to increase 
the power of the present study by focusing our efforts on the most severe form of sepsis, 
septic shock, which may involve alleles of larger effect. Additionally, we performed a suite of 
gene-based, pathway-based, and polygenic score analyses which have greater statistical 
power than single locus tests of association. 
One SNP, rs9489328, was genome-wide significantly associated with susceptibility to septic 
shock. The rs9489328 SNP lies physically within an uncharacterised non-coding RNA 
(AL589740.1), with no known biological functions. This variant has not been previously 
significantly associated with any traits. The SNPs that are in linkage disequilibrium with it are 
not associated with the phenotype (Supplementary Table S8), hence the lack of ‘peak’ typical 
of true associations. Although rs9489328 passed all QC steps, it is possible that the 
association reflects a false positive and may be a genotyping artefact or a product of batch 




discussion of the four SNPs, rs368584, rs11167801, rs7698838, and rs17128291, which 
reached suggestive levels of significance can be found in the Supplementary Discussion S1. 
The results from the present GWAS have not identified common variants of large effect 
contributing to susceptibility to, mortality from, and resolution of septic shock.  
Despite being adequately powered, we failed to replicate previous SNP associations (which 
were notably rare variants; see Supplementary Table S3 and Supplementary Table S4) with 
sepsis in this study. This could be due to variability in the phenotype definitions, although 
this may be unlikely considering the variants contributing to the sepsis phenotype would 
likely be enriched in a cohort of septic shock individuals. Additionally, the previous studies 
used controls who had been exposed to sepsis risk factors, while this is ideal, we consider the 
reduction in power we experienced due to using population controls to be minimal give the 
low incidence of sepsis in the population (and likely in our controls)- and not the reason we 
were unable to replicate previous findings. Instead, the genetic variants prioritised in previous 
sepsis GWAS may be spurious associations arising from small cohort sizes.  
Gene-based analyses failed to identify any genes significantly associated with the tested 
phenotypes. However, the top results for each analysis consisted of a number of 
cardiovascular and immune related genes. Variants within KLB, NINJ2, and SS18 have been 
previously associated with cardiovascular related phenotypes (Ikram et al., 2009; Astle et al., 
2016; Kanai et al., 2018; Giri et al., 2019; Kichaev et al., 2019). Likewise, NINJ2 and 
CMTM7 have been associated with immune phenotypes(Astle et al., 2016; Jonsson et al., 
2017). Given the previous associations of variants within these genes with cardiovascular and 
immune disorders, and observed increased risk of sepsis in individuals with chronic medical 
conditions, a connection with the pathophysiology of septic shock and may be biologically 
plausible, and may provide possible therapeutic targets given replication and functional 




This study was the first to conduct PRS analyses in a cohort of  patients with septic shock and 
the results indicate that correlation between septic shock and a number of clinically relevant 
phenotypes are not only observed at the phenotypic level, as seen in observational studies, but 
are also reflected at the genetic level. Future Mendelian randomization analyses in larger 
genetic cohorts may help ascertain whether the PRS associations reflect a genetic overlap or a 
causal relationship (Davey Smith & Ebrahim, 2003). This may overcome confounding if the 
assumptions are met, and may provide valid targets for therapeutics. 
The PRS analyses found increased CRP levels were predictive of increased susceptibility to 
septic shock. CRP is an acute-phase protein synthesised predominantly by liver cells in 
response to inflammatory cytokines, mainly interlukin 6, and therefore levels rise during 
inflammation (Ligthart et al., 2018). One interpretation of a significant association between 
PRS for CRP and septic shock is that increased CRP levels are causally related to an 
increased risk of septic shock. However, we consider this explanation unlikely to be true, 
because PRS from the most strongly CRP associated SNPs (i.e. PRS consisting of only 
genome-wide significant variants for CRP) were not associated with septic shock, despite 
previous research showing genome-wide significant SNPs explain more variance in CRP 
levels than PRS including SNPs reaching less stringent thresholds (Ligthart et al., 2018; 
Evans et al., 2013). More likely, the result could reflect a genetic overlap with potential 
underlying genetic inflammatory disorders which contribute to increased circulating CRP 
levels, and also increased risk of septic shock (Muller et al., 2005; Wang et al., 2012). For 
example, individuals with a genetic predisposition to increased CRP levels (likely actually 
reflecting underlying genetic inflammatory disorders which increase CRP levels) may 
respond to a severe infection with a more pronounced inflammatory response, resulting in 




PRS for granulocyte count were negatively associated with 28-day mortality. The direction of 
the association suggests a genetic predisposition to higher granulocyte count is associated 
with decreased patient mortality, possibly because of a better immune response and 
successful clearing of the infection, which is supported in the literature (Bermejo-Martín et 
al., 2014). 
PRS for decreased hematocrit levels were associated with increased 28-day mortality. 
Although the primary role of red blood cells is the transport of oxygen, they also mediate 
innate immunity through binding chemokines, pathogens, and nucleic acids (Anderson et al 
2018). Sepsis patients present with high hematocrit due to capillary leak syndrome, and this 
could be related to an adverse outcome (van Beest et al., 2008).  However the PRS reflect 
hematocrit in “healthy” individuals, and due to their immune role, a genetic predisposition to 
decreased red blood cell count (and thus lower hematocrit), could alter the host’s ability to 
mount an effective immune response. 
The main limitation of the present study was a lack of statistical power primarily due to small 
sample size caused by the logistical difficulty of collecting biological samples in intensive 
care settings in a timely manner from a large number of sepsis patients. Additionally, power 
may have been reduced due to disease heterogeneity and misclassification bias. As sepsis is 
triggered by an environmental cue (i.e. infection), it is possible that some controls would in 
fact have been cases had they been exposed to the relevant environment, or may have already 
survived a sepsis episode, however this reduction in power is small given the low incidence 
of sepsis. Whilst we were underpowered to detect loci of small effect at genome-wide levels 
of significance, our results show common variants of large effect (e.g. variants in the major 
histocompatibility region which are known to contribute to many immune mediated diseases) 




Although extensive molecular studies into sepsis and septic shock have been performed, 
genetic analyses have been limited despite longstanding evidence of a strong genetic 
component to the disease.  
Sepsis is likely a complex trait, and hence will be influenced by many genetic variants with 
small effect. A large meta-analysis would be better powered to detect genetic variants with 
smaller effects that likely contribute to septic shock mortality/susceptibility, and may permit 
calculations using LD score regression, and place a lower bound on sepsis heritability (Bulik-
Sullivan et al., 2015). 
In conclusion, our polygenic risk score analyses identified several associations between 
genetic risk scores for clinically relevant variables and septic shock indicating shared 
underlying genetic aetiology with comorbid traits. This report in an exclusive cohort of 
patients with established septic shock represents a key step in understanding the genetic basis 
of septic shock and may inform the debate on future therapeutic targets for the condition.  
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Table 1. Characteristics of ADRENAL-GWAS Patients Prior to Randomisation and 




Septic shock* 493 cases 2442 controls 2935 
90-day mortality  112 non-
survivors  
381 survivors  493 
28-day mortality 90 non-
survivors 
403 survivors 493 














65/112 (58.04%) 200/381 
(52.49%) 
0.35 
Re-admission (yes/no) 108/492 † 
(21.95%) 
29/112 (25.89%) 79/380 (20.79%) 0.27 
Sex (female/male) 183/493 
(37.11% ) 
45/112 (40.18%) 138/381 
(36.22%) 
0.52 
Use of renal replacement 
therapy  (yes/no) 
141/491 
(28.72%) 
55/111 (49.55%) 86/380 (22.63%) 6.85 x 10-8 
Bacteraemia (yes/no) 75/490 
(15.31%) 












Age (years) 63.80 
(14.72) 
69.67 (12.85) 62.08 (14.78) 3.18 x 10-7 
APACHE (II) score 23.28 
(6.97) 
26.30 (7.37) 22.39 (6.59) 1.26 x 10-6 
Weight (kg) 89.72 
(29.04) 
87.93 (31.24) 90.25 (28.33) 0.48 
Time to resolution of 
shock (days) 
4.55 (5.12) 5.54 (5.66) 3.88 (4.89) 5.52 x 10-3 
Base temperature (°C) 37.31 
(1.02) 
36.96 (1.04) 37.41 (0.99) 8.98 x 10-5 
Base heart rate (bpm) 91.26 
(20.04) 
92.54 (19.37) 92.18 (20.24) 0.87 
Base central venous 
pressure (mm Hg) 
12.20 
(5.72) 
13.43 (6.67) 11.84 (5.36) 0.06 
Lowest mean arterial 
pressure (mm Hg) 
58.13 
(7.87) 
57.88 (9.10) 58.21  (7.47) 0.72 
Lowest Pa2:F2  165.23 
(86.11) 
155.03 (82.37) 168.20 (86.95) 0.15 
Highest arterial lactate 
(mg/dl) 
3.39 (2.66) 4.55 (3.07) 3.06 (2.43) 6.21 x 10-6 
Highest bilirubin (mg/dl) 31.49 
(38.85) 
45.01 (59.59) 27.51 (28.95) 3.48 x 10-3 





Lowest haemoglobin (g/L) 104.44 
(22.84) 
101.91 (23.75) 105.18 (22.52) 0.20 




16.75 (9.58) 17.17  (10.99) 0.69 






219.14 (120.89) 0.01 
Highest international 
normalised ratio 
1.65 (0.83) 1.93 (0.97) 1.56 (0.76) 5.95 x 10-4 
Reported is the ratio and percentage for dichotomous characteristics, and the mean and 
standard deviation (SD) for quantitative traits. Scores on the Acute Physiology and Chronic 
Health Evaluation (APACHE) II assess the severity of disease, ranging between 0 (low risk 
for death) and 71 (high risk). A Student’s t-test was used to test for differences in the mean 
quantitative traits between 90-day survivors and non-survivors. A Chi-squared Test of 
Independence was used to test for difference in dichotomous traits between 90-day survivors 
and non-survivors. * The susceptibility to septic shock analyses were the only analyses 























Septic shock rs9489328 6:98104575 Intronic 
AL589740.1 
0.10 T/G 0.37 (0.15) *1.05 x 10-10 
Shock 
resolution 
rs11167801 5:142470334 Intronic 
ARHGAP26 
0.09 T/C 0.13 (0.39) 8.77 x 10-8 
28-day 
mortality 
rs368584 13:111145073 Intronic 
COL4A2 
0.39 G/C 2.56 (0.18) 2.55 x 10-7 
Shock 
resolution 
rs7698838 4:58088682 Intergenic 0.07 C/T 0.15 (0.38) 6.11 x 10-7 
Shock 
resolution 
rs17128291 14:92882826 Intronic 
SLC24A4 
0.18 G/A 0.22 (0.30) 7.48 x 10-7 
Lead single nucleotide polymorphisms (SNPs) with minor allele frequency (MAF) < 5% were 
removed. The MAF, odds ratio, and standard error (SE) correspond to the minor allele. The 





Table 3. FastBAT Results for the Outcomes (A) Susceptibility to Septic shock, (B) 28-Day Mortality, (C) 90-Day Mortality, and (D) 
Shock Resolution. 
 Gene # of 
SNP
s 
P-Value Top SNP Top 
SNP P-
Value 
Gene Ontology Annotations Genome-Wide Significant GWAS Catalog 
Associations 
A) IPO5 154 5.06 x 
10-5 
rs34511977 2.76 x 
10-6 
Protein transporter activity - 
KLB 142 1.90 x 
10-4 
rs7685429 5.60 x 
10-5 
Hydrolase activity, hydrolyzing 
O-glycosyl compounds, 
fibroblast growth factor binding 
Alcohol consumption, blood urea nitrogen 
levels, pulse pressure 




GTPase binding, protein import 
into nucleus 
Vital capacity, height, initial pursuit 
acceleration in psychotic disorders 







CMTM7 219 3.12 x 
10-4 
rs6550132 4.53 x 
10-4 
 Cytokine activity, B-1a B cell 
differentiation, chemotaxis, 
signal transduction 
IgM levels, adolescent idiopathic scoliosis 
B) RAB20 240 2.18 x 
10-4 
rs368584 2.55 x 
10-7 
GTPase activity, endosome Acute myeloid leukemia, hair colour 
MIR1909 107 3.98 x 
10-4 
rs35202074 6.16 x 
10-5 
- - 
KTN1-AS1 68 5.26 x 
10-4 
rs10145555 8.78 x 
10-5 
- Putamen volume 





AS1 10-4 10-7 
NINJ2 339 7.15 x 
10-4 
rs35557779 6.21 x 
10-5 
Integral component of plasma 
membrane, neuron cell-cell 
adhesion, tissue regeneration, 
nervous system development 
Platelet distribution width, platelet count, 
plateletcrit, lymphocyte counts, granulocyte 
percentage of myeloid white cells, stroke, 
monocyte count, monocyte percentage of 
white cells, white blood cell count 
C) BRSK1 161 7.64 x 
10-5 
rs10403600 6.49 x 
10-5 
Magnesium ion binding, protein 
kinase activity, protein 
serine/threonine kinase activity 
Age at menopause, age at menarche 
TMEM150
B 
156 2.34 x 
10-4 
rs10403600 6.49 x 
10-5 
Autophagy, regulation of 
autophagy,  
Age at menopause, unipolar depression 
NMUR1 79 3.29 x 
10-4 
rs72989550 5.08 x 
10-5 
Neuromedin U receptor activity, 
G protein-coupled receptor 
activity 
Height 
HSPBP1 152 3.44 x 
10-4 
rs10403600 6.49 x 
10-5 
Adenyl-nucleotide exchange 
factor activity, enzyme inhibitor 
activity, protein binding, 
ubiquitin protein ligase binding 
- 
NINJ2 340 4.84 x 
10-4 
rs10849390 9.75 x 
10-5 
Integral component of plasma 
membrane, neuron cell-cell 
adhesion, tissue regeneration, 
nervous system development 
Platelet distribution width, platelet count, 
plateletcrit, lymphocyte counts, granulocyte 
percentage of myeloid white cells, stroke, 
monocyte count, monocyte percentage of 
white cells, white blood cell count 
D) SS18 71 3.63 x 
10-5 
rs765529 3.32 x 
10-6 
Transcription coactivator 
activity, protein binding, nuclear 
receptor transcription 






The top five genes associated with the primary outcomes are tabulated, along with the number of single nucleotide polymorphisms (SNPs) 
within the gene region, the gene-based test p-value, the most significant SNP within the region, and the respective p-value from the genome-
wide association study (GWAS), interesting gene ontology annotations, and previous associations listed within the GWAS Catalog (MacArthur 
et al., 2017). The FastBAT analyses were carried out using the Complex-Traits Genetics Virtual Lab (Bakshi et al., 2016; Cuéllar-Partida et al., 
2019). 
coactivator activity 
PSMA8 84 3.71 x 
10-5 
rs9304490 4.20 x 
10-6 
Antigen processing and 
presentation of exogenous 
peptide antigen via HLA, 
MAPK cascade, protein 
polyubiquitiation, stimulatory 
C-type lectin receptor signalling 
pathway 
- 
SLC24A4 383 2.79 x 
10-4 
rs17128291 7.48 x 
10-7 
Calcium channel activity, 
symporter activity, antiporter 
activity 
Hair colour, eye colour, suntan, Alzheimer’s 
disease  
MIR4282 58 5.06 x 
10-4 
rs12664923 3.33 x 
10-5 
- - 
NANS 82 7.37 x 
10-4 


















Septic Shock 28-Day Mortality 
Direction P-Value Direction P-Value 
C-Reactive 
Protein levels 
< 1 267725 + 2.23 x 10-3 - 2.78 x 10-1 
< 0.5 202435 + 1.44 x 10-3 - 3.02 x 10-1 
< 0.01 13767 + 2.22 x 10-2 + 8.53 x 10-1 
< 5.00 x 10-6 330 + 3.90 x 10-1 + 1.48 x 10-1 
< 5.00 x 10-8 167 - 9.79 x 10-1 + 1.16 x 10-1 
Granulocyte 
Count 
< 1 334324 + 5.89 x 10-1 - 2.29 x 10-3 
< 0.5 244497 + 5.29 x 10-1 - 2.61 x 10-3 
< 0.01 15157 + 8.08 x 10-1 - 1.07 x 10-1 
< 5.00 x 10-6 698 + 9.16 x 10-1 - 2.31 x 10-1 





< 1 320701 - 7.22 x 10-2 - 7.97 x 10-1 
< 0.5 242169 - 3.70 x 10-2 - 6.33 x 10-1 
< 0.01 21859 - 2.69 x 10-2 + 2.84 x 10-2 
< 5.00 x 10-6 806 - 2.41 x 10-2 - 9.84 x 10-1 
< 5.00 x 10-8 308 - 3.51 x 10-1 - 7.48 x 10-1 
Hematocrit < 1 334250 - 9.12 x 10-1 - 3.04 x 10-3 
< 0.5 244826 + 9.54 x 10-1 - 4.27 x 10-3 
< 0.01 15278 + 8.05 x 10-1 - 1.28 x 10-1 
< 5.00 x 10-6 621 - 5.52 x 10-1 - 3.80 x 10-1 
< 5.00 x 10-8 306 - 9.34 x 10-1 - 3.57 x 10-1 
White Blood 
Cell Count 
< 1 333971 + 2.76 x 10-1 - 4.20 x 10-1 
< 0.5 244165 + 2.24 x 10-1 - 4.05 x 10-1 
< 0.01 15586 + 9.86 x 10-2 - 4.91 x 10-1 
< 5.00 x 10-6 808 + 6.68 x 10-1 + 7.14 x 10-1 
< 5.00 x 10-8 453 + 7.57 x 10-1 + 8.33 x 10-1 
Coronary Artery 
Disease 
< 1 122441 - 1.85 x 10-1 - 1.79 x 10-1 
< 0.5 93427 - 1.55 x 10-1 - 2.27 x 10-1 
< 0.01 6784 - 3.54 x 10-1 - 3.63 x 10-1 
< 5.00 x 10-6 57 - 8.67 x 10-1 - 9.34 x 10-1 
< 5.00 x 10-8 20 - 9.69 x 10-1 - 2.28 x 10-1 
Type 2 Diabetes < 1 341453 - 9.66 x 10-1 - 9.83 x 10-1 
< 0.5 252082 - 8.15 x 10-1 + 9.33 x 10-1 
< 0.01 19284 - 7.26 x 10-1 + 6.10 x 10-1 









< 1 321265 + 1.94 x 10-1 + 2.84 x 10-1 
< 0.5 235509 + 1.71 x 10-1 + 2.38 x 10-1 
< 0.01 11267 - 9.80 x 10-1 + 1.01 x 10-1 
< 5.00 x 10-6 60 + 2.02 x 10-1 + 5.91 x 10-1 




< 1 321253 + 6.90 x 10-1 + 5.60 x 10-1 
< 0.5 235757 + 7.10 x 10-1 + 5.79 x 10-1 
< 0.01 11346 + 2.89 x 10-2 + 3.42 x 10-1 
< 5.00 x 10-6 19 - 6.72 x 10-1 - 8.10 x 10-1 
< 5.00 x 10-8 3 - 3.41 x 10-1 + 5.41 x 10-1 
Height < 1 124453 + 7.07 x 10-2 + 4.90 x 10-1 
< 0.5 102079 - 7.14 x 10-2 + 4.95 x 10-1 
< 0.01 29680 - 2.51 x 10-1 + 6.43 x 10-1 
< 5.00 x 10-6 8442 - 7.26 x 10-1 - 8.61 x 10-1 
< 5.00 x 10-8 5416 - 7.87 x 10-1 + 9.80 x 10-1 
Septic shock patients (ADRENAL-GWAS) and population controls (QIMRB) were scored on 
their genotypes at single nucleotide polymorphisms (SNPs; weighted by the reported effect 
sizes) that reached various p-value thresholds (< 5 x 10-8, 5 x 10-6, 0.01, 0.5, and 1) in nine 
genome-wide association studies (GWAS) for traits of interest. The number of SNPs (N 
SNPs) included in each analysis is tabulated. Regressions for septic shock and 28-day 
mortality were performed, with standardised PRS as a predictor, and the top five principal 
components as covariates (as well as age and sex for 28-day mortality). The direction of the 
beta coefficient is noted, where a positive coefficient indicates a positive association with the 
tested phenotype (i.e. increased propensity to septic shock and/or increased risk of mortality 
at 28 days), and vice-versa for negative coefficients. Bolded p-values indicate statistically 
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